Guidance

Pertussis vaccination, dTaP/IPV (Boostrix-IPV® or Repevax®): PGD template

PGD template to support the national pertussis vaccination for pregnant women programme and vaccination of contacts of pertussis in accordance with guidelines.

From:
UK Health Security Agency
Published
7 January 2016
Last updated
2 March 2023 — See all updates

Documents

Pertussis Vaccine Patient Group Direction

Ref: UKHSA publications gateway number GOV-14321

MS Word Document, 143 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template supports the administration of low dose diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (dTaP/IPV) to:

It is valid from 31 March 2023 to 31 March 2025.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy and procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.

Published 7 January 2016
Last updated 2 March 2023 + show all updates

  1. Added version 06.00 - see page 3 for change history.

  2. Added version 05.00 - see page 2 for change history.

  3. Added version V04.00 - updated as routine review prior to PGD expiry (see document change history) and included immunisation of contacts of pertussis.

  4. Updated vaccine eligibility changed from 20 weeks to 16 weeks of pregnancy.

  5. Updated pertussis pregnancy PGD: vaccine eligibility changed from 28 to 20 weeks of pregnancy.

  6. First published.

Related content